Ed Gillis is a researcher, product developer, and entrepreneur who has built from scratch and provided leadership for early-stage medical device and pharmaceutical companies, R&D teams, and manufacturing organizations. He was involved with the development of many products including implants for treating obstructive sleep apnea, implantable osmotic pumps for delivery of drugs for treatment of chronic pain, coronary angioplasty and electrophysiology mapping and ablating catheters, and drug delivery scaffolds for treating chronic rhinosinusitis. Mr. Gillis has proven success in early and mid-stage fundraising in several medical device and specialty pharma companies, including ReVENT Medical, a company that he founded. He has expertise in medical device/pharmaceutical product development, conducting pre-clinical and early clinical studies, and clinical manufacturing in an FDA and CE compliant environment. Mr. Gillis has 34 issued US Patents and 100+ worldwide patents and applications, with extensive experience in intellectual property structuring. He has publications in the areas of drug delivery, including the delivery of carboplatin to the brainstem of primates as well as the treatment of obstructive sleep apnea with implants. Mr. Gillis has been CEO for Revolution Contraceptives since early 2017, focused on developing our SMA polymer hydrogel implant and the associated placement and reversal procedures for future pre-clinical and clinical studies.